Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-02-21
2006-02-21
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S055100, C530S395000, C435S455000
Reexamination Certificate
active
07001891
ABSTRACT:
The present invention provides a biodegradable polycation composition for delivery of an anionic macromolecule, comprising a polysaccharide chain having an amount of saccharide units ranging from 2 to 2000 and at least one grafted oligoamine per 5 saccharide units, wherein said oligoamine is selected from the group consisting of a linear, branched and cyclic alkyl amine having at least two amino groups.
REFERENCES:
patent: 3225012 (1965-12-01), Black et al.
patent: 4146515 (1979-03-01), Buikema et al.
patent: 5312967 (1994-05-01), Kiely et al.
patent: 5329044 (1994-07-01), Kiely et al.
patent: 5434233 (1995-07-01), Kiely et al.
patent: 5473035 (1995-12-01), Kiely et al.
patent: 5567685 (1996-10-01), Linden et al.
patent: 5833230 (1998-11-01), Nakagawa et al.
patent: 6011008 (2000-01-01), Domb et al.
patent: 0 370 810 (1989-11-01), None
patent: 2027190 (1995-01-01), None
patent: WO 93/25239 (1993-12-01), None
patent: WO 95/30020 (1995-12-01), None
patent: WO 98/01162 (1996-01-01), None
patent: WO 97/46223 (1997-12-01), None
patent: WO 98/27209 (1998-06-01), None
Amselem, et al., “Lipospheres for Vaccine Delivery,” InMicroparticulate Systems for Drug Delivery(Berstein, et al., eds.), pp. 149-168, 1996.
Byk, et al., “Novel cationic lipids for gene delivery and gene therapy,”Exp. Opin. Ther. Patents8(9):1125-1141 (1998).
Domb, et al., “Lipospheres for Controlled Delivery of Substances,” inNanosphere Delivery Systems(Benita, et al., eds.), pp. 377-410, 1996.
Domb, et al., “Polymers in gene therapy,” inFrontiers in Biological Polymer Applications(Ottenbrite, ed.) Technomic: Lancaster, vol. 2, pp. 1-16 (1999).
Kiely, et al., “Hydroxylated nylons based on uprotected esterified D-glucaric acid by simple condensation reactions,”J. Am. Chem. Soc.116:571-578 (1994).
Ledley, “Nonviral gene therapy: the promise of genes as pharmaceutical products.”Hum. Gene Ther.6(9): 1129-1144 (1995).
Liu, et al., “Sugar-containing polyamines prepared using galactose oxidase coupled with chemical reduction,”J. Am. Chem. Soc.121:466-467 (1999).
Mao, et al., “DNA-chitosan nanospheres: derivitization and storage stability,”Proc. Intl. Symp. Control Rel. Bioact. Matter24: 671-672 (1997).
Pitha, et al., “Detergents linked to polysaccharides:preparation and effects on membranes and cells,”Eur. J. Biochem.94(1): 11-18 (1979).
Richardson, et al., “Evaluation of highly purified chitosan as a potential gene delivery vector,”Proceed Intl. Symp. Control Rel. Bioact. Matter24: 649-650 (1997).
Takakura, et al., “Control of pharmaceutical properties of soybean tyrosine inhibitor by conjugation with dextran 1: synthesis and characterization,”J. Pharm. Sci.78(2): 117-121 (1999).
Treco and Selden, non viral gene therapy,Molec. Med. Today1(7):299-348 (1995).
Walsh, et al., “Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis,”Proc. Intl. Sym. Control. Rel. Bioact. Mater.24: 75-76 (1997).
Yamaoka, et al., “Effect of cation content of polycation-type gene carriers on in vitro gene transfer,”Chemistry Letters, 1171-1172 (1998).
Efrat Biopolymers Limited
Krishnan Ganapathy
Pabst Patent Group LLP
Wilson James O.
LandOfFree
Biodegradable polycation composition for delivery of an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biodegradable polycation composition for delivery of an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biodegradable polycation composition for delivery of an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3680862